Zevra Therapeutics financials
$10.97−3.26%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $106.5M | $23.6M | $27.5M |
| Gross profit | $90.0M | $16.2M | $25.3M |
| Gross margin | 84.5% | 68.6% | 92.1% |
| Operating income | -$62.9M | -$87.0M | -$49.6M |
| Net income | $83.2M | -$105.5M | -$46.0M |
| Net margin | 78.2% | −446.9% | −167.7% |
| Diluted EPS | $1.35 | $-2.28 | $-1.30 |
| EBITDA | -$179.0K | -$80.6M | -$48.6M |
| Operating cash flow | -$1.6M | -$69.7M | -$33.5M |
| Free cash flow | -$2.4M | -$69.7M | -$33.8M |
| Diluted shares | 57.3M | 46.3M | 35.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $62.4M | $33.8M | $43.0M |
| Short-term investments | $128.6M | $35.7M | $24.7M |
| Total debt | $61.9M | $59.5M | $42.8M |
| Total assets | $284.7M | $178.1M | $172.3M |
| Total liabilities | $130.1M | $138.5M | $110.5M |
| Shareholders' equity | $154.7M | $39.7M | $61.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology